CLA (Conjugated Linoleic Acid) for Weight Loss Support

CLA (conjugated linoleic acid) is one of the most-studied weight-loss supplements, and the verdict is consistent: it works a little, not enough to matter. The largest meta-analysis, 70 randomised trials with 4,159 adults, found 0.35 kg more weight loss and 0.44 kg more fat loss than placebo. When only high-quality trials were analysed, the fat loss disappeared.

Other reviews land in the same place. In trials lasting at least 6 months, CLA beat placebo by 0.70 kg of weight and 1.33 kg of fat, but four of the seven trials had serious reporting flaws. A 2021 review of weight-loss supplements found 1.08 kg extra weight loss, well below its 2.5 kg threshold for a clinically meaningful effect. Against that small benefit sit signals of worse insulin sensitivity and higher inflammatory markers, covered below and on our CLA and insulin sensitivity page.

CLA is a family of isomers of linoleic acid, an omega-6 fat. In mice, the trans-10,cis-12 isomer sharply reduces fat gain; the cis-9,trans-11 isomer, the main one in dairy and beef, does much less. Supplements contain about equal amounts of both.

Reviews of the animal and human work list several proposed routes: lower energy and food intake, higher energy expenditure, less fat synthesis, more fat breakdown and fat oxidation, and fewer new fat cells forming from precursor cells (preadipocytes).

The same reviews note that the fat-loss effects in people are marginal and inconsistent compared with rodents, so the mechanisms say little about how much CLA can do in humans. In mice, CLA also caused insulin resistance and fatty liver.

In people, the trans-10,cis-12 isomer that is thought to drive fat loss is also the one that raised oxidative stress and C-reactive protein and worsened insulin sensitivity in obese men. The active ingredient for fat and the main safety concern appear to be the same molecule.

Most trials used about 3-3.4 g of CLA a day, usually as a 50:50 mix of the two main isomers. A 2007 meta-analysis of 18 trials estimated fat loss of 0.09 kg a week versus placebo at the median dose of 3.2 g, building for about 6 months and levelling off by 2 years.

Higher doses may add a little, at a cost. In a 12-week trial, 6.4 g a day raised lean mass by 0.64 kg but also raised C-reactive protein, IL-6 and white cell counts and lowered HDL cholesterol. In a 2019 meta-analysis, doses above 3.4 g a day were linked to slightly more weight loss (0.77 kg), but that was a subgroup comparison. Labels often state total oil per softgel, so check the CLA content.

A 2024 dose-response meta-analysis of 70 RCTs with 4,159 adults found that CLA lowered body mass by 0.35 kg, waist circumference by 0.62 cm, fat mass by 0.44 kg and body fat percentage by 0.77%, and raised fat-free mass by 0.27 kg. In the high-quality trials, fat mass and body fat percentage did not change, and the authors judged the weight effect unlikely to be clinically important.

Earlier reviews agree. A 2019 meta-analysis of 13 trials in overweight and obese adults found 0.52 kg less weight and 0.61 kg less fat, with no change in waist circumference. A 2012 review of trials lasting at least 6 months found 0.70 kg less weight and 1.33 kg less fat, and concluded that CLA does not convincingly produce clinically relevant long-term effects. A 2024 review in people at cardiovascular risk found 0.72 kg less weight.

The strongest positive trial ran for a year in 180 overweight adults: body fat was 7-9% lower than with placebo. In its open-label extension, people switched from placebo lost 1.7 kg of fat, while those already on CLA lost no more, consistent with an effect that plateaus.

Other well-run trials found nothing. An 8-week crossover trial in 27 overweight men found no change in weight, body composition or lipids, and a 12-week trial in 40 adults found no change in BMI, total fat, or abdominal and liver fat on CT, while blood-vessel function worsened. Adding CLA to exercise trimmed body fat slightly more than exercise alone but did not reduce body weight.

No trial shows that CLA improves outcomes people care about beyond the scale, such as blood pressure, diabetes risk or long-term weight maintenance. Most trials ran for 12 weeks to a year, many were small, and several of the long trials came from the same research group. In children, one 7-month trial slowed fat gain but lowered HDL cholesterol and bone mineral gain, so CLA is not a children's weight-loss aid.

Most people tolerate 3-6 g a day; digestive effects such as constipation, diarrhoea and soft stools are the usual complaints. The concerns are metabolic. The trans-10,cis-12 isomer raised C-reactive protein by 110% and an oxidative-stress marker by 578% in men with metabolic syndrome, and a meta-analysis of 11 trials found CRP rose by 0.89 mg/L on average, although a 2023 meta-analysis in people at cardiovascular risk found no change.

Rare case reports describe severe liver injury in people taking CLA weight-loss products, including liver failure needing a transplant. Causality is hard to prove in single cases, but stop at once and seek care if you notice jaundice, dark urine or itching.

No formal drug-interaction studies exist for CLA. The practical conflicts follow from its effects in trials: it can push glucose up, and severe liver injury has been reported with CLA weight-loss products.